FORM 11

NOTICE OF PROPOSED RSU GRANT

Name of Listed Issuer: <u>Treatment.com Al Inc.</u> (the "Issuer").

Trading Symbol: TRUE

Date: <u>April 16, 2024</u>

1. New RSU's Granted:

Date of Grant: April 16, 2024

Name	Position (Director/ Officer/ Employee/ Consultant/ Management Company	Insider Yes or No?	No. of RSU Shares	Expiry Date	No. of RSU's Granted in Past 12 Months
	Consultant	No	01101100		Nil
Kirolloss Beshay			500,000	April 16, 2027	
Yazan Al Homsi	Consultant	No	200,000	April 16, 2027	Nil
Kevin Peterson	Officer/Director	Yes	100,000	April 16, 2027	150,000

Total Number of RSU shares proposed for acceptance: 800,000

2. Other Presently Outstanding RSU's

Name of Holder	No. of RSUs	Original Date of Grant	Expiry Date
Dr. Essam Hamza	1,000,000	Oct 17, 2023	Oct 17, 2026
Kevin Peterson	150,000	Oct 17, 2023	Oct 17, 2028
Synergistica Services Inc.	100,000	Nov 17, 2023	May 17, 2024
John Fraser	50,000	Feb 8, 2024	Feb 8, 2027
HW Five, Inc. DBA Growthpath Partners	60,000	Feb 8, 2024	Feb 8, 2027

(1) Set out number of RSU shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of RSU's (including prior approval of a RSU plan), state the date that the shareholder meeting approving the grant was or will be held. <u>December 28, 2021.</u>
- (b) State the date of the news release announcing the grant of RSU shares. <u>April</u> 17, 2024
- (c) State the total issued and outstanding share capital at the date of grant or amendment. 39,223,518.
- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive RSU's, including new RSU's, amended RSU's and other presently outstanding RSU's. 5.51%
- (e) If the new RSU are being granted pursuant to a RSU plan, state the number of remaining shares reserved for issuance under the plan. <u>1,762,352.</u>
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors. \$0.40.
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer. N/A.

4. Certificate of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated April 16, 2024

<u>Dr. Essam Hamza</u> Name of Director or Senior Officer

<u>"Dr. Essam Hamza"</u> Signature

CEO
Official Capacity